NCT01508949View on ClinicalTrials.gov

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

March 31, 2002

Study Completion Date

March 31, 2002

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously

DRUG

placebo

Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously

Trial Locations (1)

1958

Novo Nordisk Investigational Site, Frederiksberg C

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY